{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-019094","form_type":"8-K","ticker":"LYRA","cik":"0001327273","company_name":"Lyra Therapeutics, Inc.","filed_at":"2022-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.242002+00:00","generated_at":"2026-06-25T21:32:01.432332+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Lyra Therapeutics Q1 2022 net loss of $7.0M; secures $100.5M private placement","bullets":["Net loss for Q1 2022 was $7.0M, compared to $7.8M in Q1 2021.","Cash and cash equivalents at March 31, 2022 were $33.8M; subsequently received $100.5M gross proceeds from April private placement.","Research and development expenses increased to $8.5M from $4.8M, driven by clinical trial costs.","ENLIGHTEN Phase 3 program for LYR-210 enrollment ongoing; ENLIGHTEN II initiation targeted mid-2022.","BEACON Phase 2 trial for LYR-220 first patient treated in Australia; Part 2 expected in U.S. in Q2 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-019094","json":"https://secwatch.observer/filing/0001564590-22-019094.json","markdown":"https://secwatch.observer/filing/0001564590-22-019094.md","text":"https://secwatch.observer/filing/0001564590-22-019094.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1327273/000156459022019094/0001564590-22-019094-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1327273/000156459022019094/lyra-8k_20220510.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T21:32:01.432332+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}